Table 2.
Grade 3 to 5 Nonhematologic Toxicities Within 2 Years After Transplantation (> 10% of patients)
| Toxicity | B-BEAM |
R-BEAM |
P | ||
|---|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | ||
| Any grade 3-5 toxicity | 67 | 65 | 46 | 43 | < .01 |
| Mucositis WHO grade 3-5 | 53 | 52 | 19 | 18 | < .01 |
| Hypotension | 11 | 10.7 | 13 | 12.1 | .83 |
| Hypoxia | 20 | 19.4 | 17 | 15.9 | .59 |
| Dyspnea | 29 | 28.2 | 25 | 23.4 | .44 |
| Diarrhea | 9 | 8.7 | 14 | 17.8 | .38 |
Abbreviations: B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.